In accord with ASX requirements, Imagion Biosystems’ quarterly financial statement Appendix 4C was lodged with the Australian Securities Exchange on 31 July, 2017, accompanied by commentary on the company’s recent IPO and management’s 12-18 month outlook.
View the Appendix 4C Announcement for Q2, 2017.
Imagion Initiates Collaboration with Wayne State University to Develop Advanced Molecular Imaging Capabilities to Enable AI Cancer Diagnostics
August 13, 2025
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging